ALBERT — All Library Books, journals and Electronic Records Telegrafenberg

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome (1984)

Rustin, M. H. A. ; Grimes, S. M. ; Kovacs, I. B. ; [et al.]

Springer

European journal of clinical pharmacology 27 (1984), S. 61-65

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: thromboxane synthetase inhibitors ; Raynaud's syndrome ; systemic sclerosis ; UK-38,485 ; ischaemic attacks ; red blood cell rheology

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Summary Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/BF00553156

Permalink

	Location	Call Number	Expected	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud’s syndrome (1984)

Rustin, M. H. A. ; Grimes, S. M. ; Kovacs, I. B. ; [et al.]

Springer

European journal of clinical pharmacology 27 (1984), S. 61-65

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: thromboxane synthetase inhibitors ; Raynaud’s syndrome ; systemic sclerosis ; UK-38,485 ; ischaemic attacks ; red blood cell rheology

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Summary Ten patients with moderate to severe Raynaud’s syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/BF02395208

Permalink

	Location	Call Number	Expected	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

hits 1 - 2 | 2 hits